Pharmaceutical

Bristol Myers Squibb reports 6% drop in Q2 2023 revenues

Bristol Myers Squibb has reported revenues of $11.2bn in the second quarter of 2023, versus $11.8bn in Q2 2022, indicating a drop of 6%.

Jul 29, 2023 - 20:00
Bristol Myers Squibb reports 6% drop in Q2 2023 revenues
Bristol Myers Squibb has reported revenues of $11.2bn in the second quarter of 2023, versus $11.8bn in Q2 2022, indicating a drop of 6%.
Read the original article

Tags:

Previous Article

Carmell to merge with regenerative medicine company Axolotl

Next Article

InSilicoTrials and Axoltis to develop drugs for neurological disorders

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin

Pharmanovia signs licence deal for Aeterna Zentaris’ Gh...

Mar 19, 2023

STAT+: Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans

STAT+: Karuna’s treatment for schizophrenia achieves st...

Mar 20, 2023

Adcentrx raises funds to advance ADCs into clinical development

Adcentrx raises funds to advance ADCs into clinical dev...

Apr 26, 2023